Seaport Therapeutics (SPTX) Corporate presentation summary

Market opportunity and unmet need

• Over 1 billion people globally live with mental illness, with depression and anxiety highly comorbid and associated with significant disability and mortality.

• Current neuropsychiatric medications have modest efficacy, slow onset, and unfavorable side effects, leaving many patients inadequately treated.

• Neuropsychiatry drug development faces high failure rates due to poor drug properties and challenging clinical studies.

Leadership and track record

• Leadership team includes founders and executives with experience in successful neuropsychiatric drug development and major biotech exits.

• Proven ability to identify drugs with validated efficacy and overcome development hurdles, as demonstrated in the Karuna case study.

Glyph™ platform and technology

• Glyph™ platform enables oral delivery of drugs previously limited by high first-pass metabolism, improving bioavailability and reducing hepatotoxicity.

• Proprietary prodrug chemistry promotes lymphatic uptake, bypassing the liver and generating new intellectual property.

• Platform validated across over 24 small molecules and supported by peer-reviewed research.